Core Viewpoint - The article highlights the importance of cancer prevention and control, particularly focusing on lung cancer, and promotes a series of educational initiatives aimed at improving public awareness and understanding of cancer treatment advancements, specifically in precision medicine and immunotherapy [1]. Group 1: Cancer Prevention and Awareness - The 31st National Cancer Prevention Week is scheduled from April 15 to 21, 2025, aimed at expanding cancer prevention education and encouraging individuals to take responsibility for their health [1]. - The "People's Good Doctor · Camellia Plan" series will feature experts discussing cancer prevention and treatment, fostering a supportive social atmosphere for cancer control [1]. Group 2: Advances in Lung Cancer Treatment - Lung cancer remains the most prevalent and deadly malignancy globally, with significant changes in treatment paradigms due to breakthroughs in precision medicine and immunotherapy [1]. - A live session on April 29 will feature experts sharing insights on how precision medicine and immunotherapy are transforming the survival rates of lung cancer patients [1]. Group 3: Expert Profiles - Liu Anwen, Director of the Lung Cancer Specialty Center at Nanchang University Second Affiliated Hospital, holds multiple leadership roles in oncology associations [2]. - Liu Siyang, a physician at Guangdong Provincial People's Hospital, is involved in clinical research and holds significant positions in clinical trial committees [2]. Group 4: Viewing Instructions - The live broadcast can be accessed through the People's Good Doctor App, specifically in the "Famous Doctor Live" section [3]. - Users can download the app from app stores or follow the instructions provided via the People's Health public WeChat account [4].

Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second half operating expenses down 31% [30] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the sales in 2023 [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with a year-on-year growth of 40% [29] - The company recorded its first revenue from the NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications of its technology [11] - There is a strong interest in potential out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - The NUQ platform has shown broad applicability across various established platforms, enhancing its market potential [14] Q&A Session Summary Question: Update on the feline cancer testing program - Management confirmed that the feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - Management indicated that there are plans for prospective studies following the results of the Leon study, with potential rapid adoption in cancer programs [86][90] Question: Insights on quarterly sales trends and outlook for 2025 - Management noted that sales were lumpy due to large customers ordering in batches, but solid growth was achieved with 120,000 tests sold [100] - Automation in central labs is expected to open up larger opportunities in 2025 [101] Question: Approach to managing financing risks - Management emphasized a tight grip on expenses and cash flows while focusing on securing licensing agreements [112] Question: Activity and interest in data rooms for licensing agreements - Management reported that the data generated exceeded expectations and has been crucial in energizing discussions with major companies [118]